1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Pemetrexed 1.2.3 Cisplatin 1.2.4 Others 1.3 Market by Application 1.3.1 Global Malignant Mesothelioma Therapeutic Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Pleural Mesothelioma 1.3.3 Peritoneal Mesothelioma 1.3.4 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Malignant Mesothelioma Therapeutic Market Perspective (2016-2027) 2.2 Malignant Mesothelioma Therapeutic Growth Trends by Regions 2.2.1 Malignant Mesothelioma Therapeutic Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Malignant Mesothelioma Therapeutic Historic Market Share by Regions (2016-2021) 2.2.3 Malignant Mesothelioma Therapeutic Forecasted Market Size by Regions (2022-2027) 2.3 Malignant Mesothelioma Therapeutic Industry Dynamic 2.3.1 Malignant Mesothelioma Therapeutic Market Trends 2.3.2 Malignant Mesothelioma Therapeutic Market Drivers 2.3.3 Malignant Mesothelioma Therapeutic Market Challenges 2.3.4 Malignant Mesothelioma Therapeutic Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Malignant Mesothelioma Therapeutic Players by Revenue 3.1.1 Global Top Malignant Mesothelioma Therapeutic Players by Revenue (2016-2021) 3.1.2 Global Malignant Mesothelioma Therapeutic Revenue Market Share by Players (2016-2021) 3.2 Global Malignant Mesothelioma Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Malignant Mesothelioma Therapeutic Revenue 3.4 Global Malignant Mesothelioma Therapeutic Market Concentration Ratio 3.4.1 Global Malignant Mesothelioma Therapeutic Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Malignant Mesothelioma Therapeutic Revenue in 2020 3.5 Malignant Mesothelioma Therapeutic Key Players Head office and Area Served 3.6 Key Players Malignant Mesothelioma Therapeutic Product Solution and Service 3.7 Date of Enter into Malignant Mesothelioma Therapeutic Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Malignant Mesothelioma Therapeutic Breakdown Data by Type 4.1 Global Malignant Mesothelioma Therapeutic Historic Market Size by Type (2016-2021) 4.2 Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Type (2022-2027) 5 Malignant Mesothelioma Therapeutic Breakdown Data by Application 5.1 Global Malignant Mesothelioma Therapeutic Historic Market Size by Application (2016-2021) 5.2 Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America Malignant Mesothelioma Therapeutic Market Size (2016-2027) 6.2 North America Malignant Mesothelioma Therapeutic Market Size by Type 6.2.1 North America Malignant Mesothelioma Therapeutic Market Size by Type (2016-2021) 6.2.2 North America Malignant Mesothelioma Therapeutic Market Size by Type (2022-2027) 6.2.3 North America Malignant Mesothelioma Therapeutic Market Size by Type (2016-2027) 6.3 North America Malignant Mesothelioma Therapeutic Market Size by Application 6.3.1 North America Malignant Mesothelioma Therapeutic Market Size by Application (2016-2021) 6.3.2 North America Malignant Mesothelioma Therapeutic Market Size by Application (2022-2027) 6.3.3 North America Malignant Mesothelioma Therapeutic Market Size by Application (2016-2027) 6.4 North America Malignant Mesothelioma Therapeutic Market Size by Country 6.4.1 North America Malignant Mesothelioma Therapeutic Market Size by Country (2016-2021) 6.4.2 North America Malignant Mesothelioma Therapeutic Market Size by Country (2022-2027) 6.4.3 United States 6.4.4 Canada 7 Europe 7.1 Europe Malignant Mesothelioma Therapeutic Market Size (2016-2027) 7.2 Europe Malignant Mesothelioma Therapeutic Market Size by Type 7.2.1 Europe Malignant Mesothelioma Therapeutic Market Size by Type (2016-2021) 7.2.2 Europe Malignant Mesothelioma Therapeutic Market Size by Type (2022-2027) 7.2.3 Europe Malignant Mesothelioma Therapeutic Market Size by Type (2016-2027) 7.3 Europe Malignant Mesothelioma Therapeutic Market Size by Application 7.3.1 Europe Malignant Mesothelioma Therapeutic Market Size by Application (2016-2021) 7.3.2 Europe Malignant Mesothelioma Therapeutic Market Size by Application (2022-2027) 7.3.3 Europe Malignant Mesothelioma Therapeutic Market Size by Application (2016-2027) 7.4 Europe Malignant Mesothelioma Therapeutic Market Size by Country 7.4.1 Europe Malignant Mesothelioma Therapeutic Market Size by Country (2016-2021) 7.4.2 Europe Malignant Mesothelioma Therapeutic Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size (2016-2027) 8.2 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Type 8.2.1 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Type (2016-2021) 8.2.2 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Type (2022-2027) 8.2.3 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Type (2016-2027) 8.3 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Application 8.3.1 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Application (2016-2021) 8.3.2 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Application (2022-2027) 8.3.3 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Application (2016-2027) 8.4 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region 8.4.1 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2016-2021) 8.4.2 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Malignant Mesothelioma Therapeutic Market Size (2016-2027) 9.2 Latin America Malignant Mesothelioma Therapeutic Market Size by Type 9.2.1 Latin America Malignant Mesothelioma Therapeutic Market Size by Type (2016-2021) 9.2.2 Latin America Malignant Mesothelioma Therapeutic Market Size by Type (2022-2027) 9.2.3 Latin America Malignant Mesothelioma Therapeutic Market Size by Type (2016-2027) 9.3 Latin America Malignant Mesothelioma Therapeutic Market Size by Application 9.3.1 Latin America Malignant Mesothelioma Therapeutic Market Size by Application (2016-2021) 9.3.2 Latin America Malignant Mesothelioma Therapeutic Market Size by Application (2022-2027) 9.3.3 Latin America Malignant Mesothelioma Therapeutic Market Size by Application (2016-2027) 9.4 Latin America Malignant Mesothelioma Therapeutic Market Size by Country 9.4.1 Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2016-2021) 9.4.2 Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size (2016-2027) 10.2 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Type 10.2.1 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Type (2016-2021) 10.2.2 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Type (2022-2027) 10.2.3 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Type (2016-2027) 10.3 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Application 10.3.1 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Application (2016-2021) 10.3.2 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Application (2022-2027) 10.3.3 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Application (2016-2027) 10.4 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country 10.4.1 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2016-2021) 10.4.2 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Eli Lilly 11.1.1 Eli Lilly Company Details 11.1.2 Eli Lilly Business Overview 11.1.3 Eli Lilly Malignant Mesothelioma Therapeutic Introduction 11.1.4 Eli Lilly Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) 11.1.5 Eli Lilly Recent Development 11.2 Teva 11.2.1 Teva Company Details 11.2.2 Teva Business Overview 11.2.3 Teva Malignant Mesothelioma Therapeutic Introduction 11.2.4 Teva Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) 11.2.5 Teva Recent Development 11.3 Sanofi 11.3.1 Sanofi Company Details 11.3.2 Sanofi Business Overview 11.3.3 Sanofi Malignant Mesothelioma Therapeutic Introduction 11.3.4 Sanofi Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) 11.3.5 Sanofi Recent Development 11.4 Bristol-Myers Squibb 11.4.1 Bristol-Myers Squibb Company Details 11.4.2 Bristol-Myers Squibb Business Overview 11.4.3 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Introduction 11.4.4 Bristol-Myers Squibb Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) 11.4.5 Bristol-Myers Squibb Recent Development 11.5 Pfizer 11.5.1 Pfizer Company Details 11.5.2 Pfizer Business Overview 11.5.3 Pfizer Malignant Mesothelioma Therapeutic Introduction 11.5.4 Pfizer Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) 11.5.5 Pfizer Recent Development 11.6 Roche 11.6.1 Roche Company Details 11.6.2 Roche Business Overview 11.6.3 Roche Malignant Mesothelioma Therapeutic Introduction 11.6.4 Roche Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) 11.6.5 Roche Recent Development 11.7 Merck 11.7.1 Merck Company Details 11.7.2 Merck Business Overview 11.7.3 Merck Malignant Mesothelioma Therapeutic Introduction 11.7.4 Merck Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) 11.7.5 Merck Recent Development 11.8 Ono Pharmaceutical 11.8.1 Ono Pharmaceutical Company Details 11.8.2 Ono Pharmaceutical Business Overview 11.8.3 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Introduction 11.8.4 Ono Pharmaceutical Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) 11.8.5 Ono Pharmaceutical Recent Development 11.9 Mylan 11.9.1 Mylan Company Details 11.9.2 Mylan Business Overview 11.9.3 Mylan Malignant Mesothelioma Therapeutic Introduction 11.9.4 Mylan Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) 11.9.5 Mylan Recent Development 11.10 Fresenius Kabi 11.10.1 Fresenius Kabi Company Details 11.10.2 Fresenius Kabi Business Overview 11.10.3 Fresenius Kabi Malignant Mesothelioma Therapeutic Introduction 11.10.4 Fresenius Kabi Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) 11.10.5 Fresenius Kabi Recent Development 11.11 Sun Pharmaceuticals 11.11.1 Sun Pharmaceuticals Company Details 11.11.2 Sun Pharmaceuticals Business Overview 11.11.3 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Introduction 11.11.4 Sun Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) 11.11.5 Sun Pharmaceuticals Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of Pemetrexed Table 3. Key Players of Cisplatin Table 4. Key Players of Others Table 5. Global Malignant Mesothelioma Therapeutic Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 6. Global Malignant Mesothelioma Therapeutic Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 7. Global Malignant Mesothelioma Therapeutic Market Size by Regions (2016-2021) & (US$ Million) Table 8. Global Malignant Mesothelioma Therapeutic Market Share by Regions (2016-2021) Table 9. Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 10. Global Malignant Mesothelioma Therapeutic Market Share by Regions (2022-2027) Table 11. Malignant Mesothelioma Therapeutic Market Trends Table 12. Malignant Mesothelioma Therapeutic Market Drivers Table 13. Malignant Mesothelioma Therapeutic Market Challenges Table 14. Malignant Mesothelioma Therapeutic Market Restraints Table 15. Global Malignant Mesothelioma Therapeutic Revenue by Players (2016-2021) & (US$ Million) Table 16. Global Malignant Mesothelioma Therapeutic Market Share by Players (2016-2021) Table 17. Global Top Malignant Mesothelioma Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Mesothelioma Therapeutic as of 2020) Table 18. Ranking of Global Top Malignant Mesothelioma Therapeutic Companies by Revenue (US$ Million) in 2020 Table 19. Global 5 Largest Players Market Share by Malignant Mesothelioma Therapeutic Revenue (CR5 and HHI) & (2016-2021) Table 20. Key Players Headquarters and Area Served Table 21. Key Players Malignant Mesothelioma Therapeutic Product Solution and Service Table 22. Date of Enter into Malignant Mesothelioma Therapeutic Market Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Global Malignant Mesothelioma Therapeutic Market Size by Type (2016-2021) (US$ Million) Table 25. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2016-2021) Table 26. Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Type (2022-2027) (US$ Million) Table 27. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2022-2027) & (US$ Million) Table 28. Global Malignant Mesothelioma Therapeutic Market Size Share by Application (2016-2021) & (US$ Million) Table 29. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2016-2021) Table 30. Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Application (2022-2027) (US$ Million) Table 31. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2022-2027) & (US$ Million) Table 32. North America Malignant Mesothelioma Therapeutic Market Size by Type (2016-2021) (US$ Million) Table 33. North America Malignant Mesothelioma Therapeutic Market Size by Type (2022-2027) & (US$ Million) Table 34. North America Malignant Mesothelioma Therapeutic Market Size by Application (2016-2021) (US$ Million) Table 35. North America Malignant Mesothelioma Therapeutic Market Size by Application (2022-2027) & (US$ Million) Table 36. North America Malignant Mesothelioma Therapeutic Market Size by Country (2016-2021) & (US$ Million) Table 37. North America Malignant Mesothelioma Therapeutic Market Size by Country (2022-2027) & (US$ Million) Table 38. Europe Malignant Mesothelioma Therapeutic Market Size by Type (2016-2021) (US$ Million) Table 39. Europe Malignant Mesothelioma Therapeutic Market Size by Type (2022-2027) & (US$ Million) Table 40. Europe Malignant Mesothelioma Therapeutic Market Size by Application (2016-2021) (US$ Million) Table 41. Europe Malignant Mesothelioma Therapeutic Market Size by Application (2022-2027) & (US$ Million) Table 42. Europe Malignant Mesothelioma Therapeutic Market Size by Country (2016-2021) & (US$ Million) Table 43. Europe Malignant Mesothelioma Therapeutic Market Size by Country (2022-2027) & (US$ Million) Table 44. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Type (2016-2021) (US$ Million) Table 45. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Type (2022-2027) & (US$ Million) Table 46. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Application (2016-2021) (US$ Million) Table 47. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Application (2022-2027) & (US$ Million) Table 48. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2016-2021) & (US$ Million) Table 49. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2022-2027) & (US$ Million) Table 50. Latin America Malignant Mesothelioma Therapeutic Market Size by Type (2016-2021) (US$ Million) Table 51. Latin America Malignant Mesothelioma Therapeutic Market Size by Type (2022-2027) & (US$ Million) Table 52. Latin America Malignant Mesothelioma Therapeutic Market Size by Application (2016-2021) (US$ Million) Table 53. Latin America Malignant Mesothelioma Therapeutic Market Size by Application (2022-2027) & (US$ Million) Table 54. Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2016-2021) & (US$ Million) Table 55. Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2022-2027) & (US$ Million) Table 56. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Type (2016-2021) (US$ Million) Table 57. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Type (2022-2027) & (US$ Million) Table 58. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Application (2016-2021) (US$ Million) Table 59. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Application (2022-2027) & (US$ Million) Table 60. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2016-2021) & (US$ Million) Table 61. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2022-2027) & (US$ Million) Table 62. Eli Lilly Company Details Table 63. Eli Lilly Business Overview Table 64. Eli Lilly Malignant Mesothelioma Therapeutic Product Table 65. Eli Lilly Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) & (US$ Million) Table 66. Eli Lilly Recent Development Table 67. Teva Company Details Table 68. Teva Business Overview Table 69. Teva Malignant Mesothelioma Therapeutic Product Table 70. Teva Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) & (US$ Million) Table 71. Teva Recent Development Table 72. Sanofi Company Details Table 73. Sanofi Business Overview Table 74. Sanofi Malignant Mesothelioma Therapeutic Product Table 75. Sanofi Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) & (US$ Million) Table 76. Sanofi Recent Development Table 77. Bristol-Myers Squibb Company Details Table 78. Bristol-Myers Squibb Business Overview Table 79. Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Product Table 80. Bristol-Myers Squibb Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) & (US$ Million) Table 81. Bristol-Myers Squibb Recent Development Table 82. Pfizer Company Details Table 83. Pfizer Business Overview Table 84. Pfizer Malignant Mesothelioma Therapeutic Product Table 85. Pfizer Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) & (US$ Million) Table 86. Pfizer Recent Development Table 87. Roche Company Details Table 88. Roche Business Overview Table 89. Roche Malignant Mesothelioma Therapeutic Product Table 90. Roche Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) & (US$ Million) Table 91. Roche Recent Development Table 92. Merck Company Details Table 93. Merck Business Overview Table 94. Merck Malignant Mesothelioma Therapeutic Product Table 95. Merck Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) & (US$ Million) Table 96. Merck Recent Development Table 97. Ono Pharmaceutical Company Details Table 98. Ono Pharmaceutical Business Overview Table 99. Ono Pharmaceutical Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) & (US$ Million) Table 100. Ono Pharmaceutical Recent Development Table 101. Mylan Company Details Table 102. Mylan Business Overview Table 103. Mylan Malignant Mesothelioma Therapeutic Product Table 104. Mylan Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) & (US$ Million) Table 105. Mylan Recent Development Table 106. Fresenius Kabi Company Details Table 107. Fresenius Kabi Business Overview Table 108. Fresenius Kabi Malignant Mesothelioma Therapeutic Product Table 109. Fresenius Kabi Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) & (US$ Million) Table 110. Fresenius Kabi Recent Development Table 111. Sun Pharmaceuticals Company Details Table 112. Sun Pharmaceuticals Business Overview Table 113. Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Product Table 114. Sun Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (2016-2021) & (US$ Million) Table 115. Sun Pharmaceuticals Recent Development Table 116. Research Programs/Design for This Report Table 117. Key Data Information from Secondary Sources Table 118. Key Data Information from Primary Sources List of Figures Figure 1. Global Malignant Mesothelioma Therapeutic Market Share by Type: 2020 VS 2027 Figure 2. Pemetrexed Features Figure 3. Cisplatin Features Figure 4. Others Features Figure 5. Global Malignant Mesothelioma Therapeutic Market Share by Application: 2020 VS 2027 Figure 6. Pleural Mesothelioma Case Studies Figure 7. Peritoneal Mesothelioma Case Studies Figure 8. Others Case Studies Figure 9. Malignant Mesothelioma Therapeutic Report Years Considered Figure 10. Global Malignant Mesothelioma Therapeutic Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 11. Global Malignant Mesothelioma Therapeutic Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 12. Global Malignant Mesothelioma Therapeutic Market Share by Regions: 2020 VS 2027 Figure 13. Global Malignant Mesothelioma Therapeutic Market Share by Regions (2022-2027) Figure 14. Global Malignant Mesothelioma Therapeutic Market Share by Players in 2020 Figure 15. Global Top Malignant Mesothelioma Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Mesothelioma Therapeutic as of 2020 Figure 16. The Top 10 and 5 Players Market Share by Malignant Mesothelioma Therapeutic Revenue in 2020 Figure 17. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2016-2021) Figure 18. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2022-2027) Figure 19. North America Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 20. North America Malignant Mesothelioma Therapeutic Market Share by Type (2016-2027) Figure 21. North America Malignant Mesothelioma Therapeutic Market Share by Application (2016-2027) Figure 22. North America Malignant Mesothelioma Therapeutic Market Share by Country (2016-2027) Figure 23. United States Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 24. Canada Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 25. Europe Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 26. Europe Malignant Mesothelioma Therapeutic Market Share by Type (2016-2027) Figure 27. Europe Malignant Mesothelioma Therapeutic Market Share by Application (2016-2027) Figure 28. Europe Malignant Mesothelioma Therapeutic Market Share by Country (2016-2027) Figure 29. Germany Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 30. France Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 31. U.K. Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 32. Italy Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 33. Russia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 34. Nordic Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 35. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. Asia-Pacific Malignant Mesothelioma Therapeutic Market Share by Type (2016-2027) Figure 37. Asia-Pacific Malignant Mesothelioma Therapeutic Market Share by Application (2016-2027) Figure 38. Asia-Pacific Malignant Mesothelioma Therapeutic Market Share by Region (2016-2027) Figure 39. China Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 40. Japan Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 41. South Korea Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 42. Southeast Asia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 43. India Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 44. Australia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 45. Latin America Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. Latin America Malignant Mesothelioma Therapeutic Market Share by Type (2016-2027) Figure 47. Latin America Malignant Mesothelioma Therapeutic Market Share by Application (2016-2027) Figure 48. Latin America Malignant Mesothelioma Therapeutic Market Share by Country (2016-2027) Figure 49. Mexico Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 50. Brazil Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 51. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 52. Middle East & Africa Malignant Mesothelioma Therapeutic Market Share by Type (2016-2027) Figure 53. Middle East & Africa Malignant Mesothelioma Therapeutic Market Share by Application (2016-2027) Figure 54. Middle East & Africa Malignant Mesothelioma Therapeutic Market Share by Country (2016-2027) Figure 55. Turkey Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 56. Saudi Arabia Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 57. UAE Malignant Mesothelioma Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 58. Eli Lilly Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2016-2021) Figure 59. Teva Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2016-2021) Figure 60. Sanofi Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2016-2021) Figure 61. Bristol-Myers Squibb Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2016-2021) Figure 62. Pfizer Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2016-2021) Figure 63. Roche Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2016-2021) Figure 64. Merck Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2016-2021) Figure 65. Ono Pharmaceutical Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2016-2021) Figure 66. Mylan Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2016-2021) Figure 67. Fresenius Kabi Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2016-2021) Figure 68. Sun Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2016-2021) Figure 69. Bottom-up and Top-down Approaches for This Report Figure 70. Data Triangulation Figure 71. Key Executives Interviewed

Eli Lilly Teva Sanofi Bristol-Myers Squibb Pfizer Roche Merck Ono Pharmaceutical Mylan Fresenius Kabi Sun Pharmaceuticals